Table 3.

Characteristics of inaccurate results from proposed automatic algorithm.

Explanation		No.	Example	PMID_txa
Limitations of SemRep
	NER error	8	bevacizumab-TREATS-Widespread Disease Cisplatin-TREATS-Widespread Disease Etoposide-TREATS-Widespread Disease	19826110.ab.12 CONCLUSION: The addition of bevacizumab to cisplatin and etoposide in patients with ED-SCLC results in …
	SPR error	17	ASA 404-TREATS-Non-Small Cell Lung Carcinoma Carboplatin-TREATS-Non-Small Cell Lung Carcinoma Paclitaxel-TREATS-Non-Small Cell Lung Carcinoma	21709202.ab.11 CONCLUSION: The addition of ASA404 to carboplatin and paclitaxel, although generally well tolerated, failed to improve frontline efficacy in advanced NSCLC.
Limitations of proposal
	Single Therapy	40	pemetrexed-TREATS-Non-small cell lung cancer metastatic erlotinib-TREATS-Non-small cell lung cancer metastatic	23661337.ab.9 CONCLUSION: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC.
	Multiple combined therapies	5	Custirsen-TREATS-Hormone refractory prostate cancer docetaxel-TREATS-Hormone refractory prostate cancer Mitoxantrone-TREATS-Hormone refractory prostate cancer	21788353.ab.15 CONCLUSION: Custirsen plus either docetaxel or mitoxantrone was feasible in patients with progressive mCRPC following first-line docetaxel therapy.

^aPMID_tx: PubMed identifier, abstract, sentence number, and associated text